Drug intelligence / Profile preview

AV-0214W

Development stage: Unknown
Lead developer: Aviex Technologies

Overview

AV-0214W is a biological product in early-stage development by Aviex Technologies. It is being investigated for the treatment of schistosomiasis, a parasitic infectious disease. The drug is currently at the discovery phase, and detailed information about its mechanism of action, molecular target(s), or specific modality has not been disclosed publicly as of June 2025. No clinical trial results or regulatory approvals are available at this time[1][2].

Targets

CTSB (Cathepsin B)

Beyond the preview

Go deeper on AV-0214W.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AV-0214W.

Explore the full profile